Antonio Giordano

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy
    A Giordano
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 23:1144-50. 2012
  2. doi request reprint CTCs in metastatic breast cancer
    Antonio Giordano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Recent Results Cancer Res 195:193-201. 2012
  3. ncbi request reprint Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients
    Antonio Giordano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
    Breast Cancer Res Treat 129:451-8. 2011
  4. doi request reprint Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer
    Ugo De Giorgi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 12:264-9. 2012
  5. doi request reprint High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer
    Simone Anfossi
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America The University of Texas Graduate School of Biomedical Sciences at Houston, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 9:e83113. 2014
  6. pmc Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients
    Antonio Giordano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 19:1596-602. 2013
  7. pmc Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer
    Antonio Giordano
    Department of Hematopathology, Unit 0054, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
    Mol Cancer Ther 11:2526-34. 2012
  8. pmc Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy
    Michal Mego
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 130:808-16. 2012
  9. pmc Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
    Mario Giuliano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Breast Cancer Res 13:R67. 2011
  10. pmc Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation
    Michal Mego
    1 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 7 Current Address National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovak Republic
    J Cancer 3:369-80. 2012

Detail Information

Publications11

  1. doi request reprint Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy
    A Giordano
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 23:1144-50. 2012
    ..We hypothesized that the relationship between CTCs and disease subtype would provide a better understanding of the clinical and biologic behavior of MBC...
  2. doi request reprint CTCs in metastatic breast cancer
    Antonio Giordano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Recent Results Cancer Res 195:193-201. 2012
    ..Theoretically, the phenotypic analysis of CTCs can represent a "liquid" biopsy of breast tumor that is able to identify a new potential target against the metastatic disease...
  3. ncbi request reprint Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients
    Antonio Giordano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
    Breast Cancer Res Treat 129:451-8. 2011
    ..This study may support the concept that the number of CTCs, along with the biologic characteristics, needs to be carefully taken into account in future analysis...
  4. doi request reprint Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer
    Ugo De Giorgi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 12:264-9. 2012
    ....
  5. doi request reprint High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer
    Simone Anfossi
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America The University of Texas Graduate School of Biomedical Sciences at Houston, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 9:e83113. 2014
    ....
  6. pmc Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients
    Antonio Giordano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 19:1596-602. 2013
    ..The objective here was to develop and validate nomograms that combined baseline CTC counts and the other prognostic factors to assess the outcome of individual patients starting first-line treatment for MBC...
  7. pmc Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer
    Antonio Giordano
    Department of Hematopathology, Unit 0054, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
    Mol Cancer Ther 11:2526-34. 2012
    ..Moreover, an enrichment of CSCs was found in CD326(-)CD45(-) cells. Additional studies are needed to determine whether EMT-CTCs and CSCs have prognostic value in patients with HER2(+) MBCs treated with trastuzumab-based therapy...
  8. pmc Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy
    Michal Mego
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 130:808-16. 2012
    ..In summary, our results demonstrate that CTCs with EMT phenotype may occur in the peripheral circulation of patients with PBC and that NAT is unable to eliminate CTCs undergoing EMT...
  9. pmc Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
    Mario Giuliano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Breast Cancer Res 13:R67. 2011
    ..We assessed the prognostic impact of CTCs according to different first-line systemic treatments, and explored their potential predictive value in MBC patients...
  10. pmc Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation
    Michal Mego
    1 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 7 Current Address National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovak Republic
    J Cancer 3:369-80. 2012
    ..Conclusion: Our data suggest that CTC and CTCs with EMT are prognostic in MBC patients undergoing HDCT followed by AHSCT...
  11. pmc Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype
    James M Reuben
    Department of Hematopathology, Unit 54, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Eur J Cancer 47:1527-36. 2011
    ..Therefore, we assessed the presence of Aldefluor(+) epithelial (CD326(+)CD45(dim)) cells for the presence of the CD44(+)CD24(lo) phenotype in BM of patients with primary breast cancer (PBC)...